On a conference call, the firm's CEO said that it and other industry players are pushing to postpone implementation of PAMA to no earlier than July 1, 2018.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Entering a new chapter with a new leader, ACLA lends support to a draft bill that would regulate lab tests not as medical devices but as in vitro clinical tests.
The AACC called for increased collaboration between physicians and laboratory medicine professionals, as Medicare changes how it reimburses for clinical lab tests.
With PAMA scheduled to be implemented in January, many believe M&A in the clinical lab space will heat up, with Quest and LabCorp the main beneficiaries.
With data analytics and more specific billing codes, the government has improved its ability to identify medically unnecessary genetic testing and other fraudulent activity.
Arriva parent firm Alere said that it would proceed with an appeal of the revocation to HHS' Department Appeals Board.
The company beat the consensus Wall Street estimates on both the top and bottom lines. It also increased its EPS outlook for full-year 2017.
Theranos was fined $30,000 by CMS. Meanwhile, it will pay $4.65 million to Arizona residents for blood testing services that it performed between 2013 and 2016.
S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.